Drug Database
CA

carteolol (OPC1085 / Ocupress / Mikelan, ophthalmic)

✓ Approved

CSL Vifor · ADRB1 · Small Molecule

What is carteolol?

carteolol is a small molecule developed by CSL Vifor. It is approved for therapeutic indications via others or topical.

Drug Profile

Brand NamesOPC1085, Ocupress, Mikelan, ophthalmic
CompanyCSL Vifor
Drug ClassSmall Molecule
Molecular TargetADRB1, ADRB2
RouteOthers, Topical
StatusApproved

Mechanism of Action

Molecular Targets

carteolol acts on 2 molecular targets:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (B2AR, ADRBR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

carteolol is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedEye and vision (London, England)2026-10-21

Blocking IL-6 trans-signaling mitigates benzalkonium chloride-induced inflammation, oxidative imbalance, ER stress, and barrier disruption in human corneal epithelial cells.

Lax Karina K, Glass Joshua J, Aliste Antonella A, Sharma Ashok A et al.

Benzalkonium chloride (BAC), a commonly used preservative in ophthalmic formulations, elicits a pro-inflammatory cytokine response and cytotoxic effects in corneal epithelial cells, contributing to ocular surface injuries associated with dry eye disease (DED). Interleukin-6 (IL-6) trans-signaling is a well-established pro-inflammatory pathway that contributes to endothelial and epithelial barrier dysfunction. Thus, this study investigated whether targeted inhibition of IL-6 trans-signaling with sgp130Fc could attenuate BAC-induced cytotoxic injury in corneal epithelial cells. Human telomerase-immortalized corneal epithelial (hTCEpi) cells were exposed to 0.001% BAC for 30 min in the presence or absence of 10 μg/mL sgp130Fc. Markers of inflammation, oxidative imbalance, endoplasmic reticulum (ER) stress, and epithelial barrier disruption were assessed using enzyme-linked immunosorbent assay, reverse transcriptase polymerase chain reaction, and western blot analyses. Reactive oxygen species (ROS), antioxidant capacity, and intracellular calcium flux were quantified using colorimetric, fluorescence-based, and luminescence-based assays. Epithelial barrier function was assessed using electric cell-substrate impedance sensing. Statistical analyses were performed using one-way analysis of variance followed by Tukey's or Holm-Šídák multiple-comparison tests, with P < 0.05 considered statistically significant. BAC exposure activated IL-6 trans-signaling as indicated by an increased sIL-6R/sgp130 ratio, reduced mIL-6R levels, and unchanged gp130 levels. BAC also increased secreted IL6 levels, IL6RA expression, and downstream inflammatory mediators MCP1 and ICAM1, all of which were attenuated by sgp130Fc. BAC-induced oxidative imbalance was characterized by increased ROS and hydrogen peroxide production, reduced antioxidant enzymes, and diminished total antioxidant capacity, whereas sgp130Fc mitigated these effects. In addition, BAC increased intracellular calcium levels and ER stress markers, including HSP72, BiP, PERK, and Ero1α, and impaired epithelial barrier function as observed by reduced trans-epithelial electrical resistance and decreased β-catenin, occludin, and claudin-1 levels. sgp130Fc mitigated increases in intracellular calcium, partially alleviated ER stress responses, and preserved epithelial barrier integrity and junctional protein levels. These findings indicate that IL-6 trans-signaling contributes to BAC-induced corneal epithelial injury, suggesting that targeting this pathway may have therapeutic potential for DED and related ocular surface inflammatory disorders.

PubMedEye (London, England)2026-10-20

Response to: 'Comment on: 'Performance of large language models for ophthalmic literature retrieval".

Paris Jai J, Kleinig Oliver O, Agarwal Ayushi A, Chan Weng Onn WO et al.

PubMedBMJ open2026-10-20

Ophthalmic surveillance before and after treatment of non-functioning pituitary adenomas with optic pathway involvement: a systematic review protocol.

Mohamed Naleer Shameer Ahmed SA, Rae Peter P, Bokre Desta D, Bremner Fion F et al.

PubMedBMJ open quality2026-10-20

Visual alert integration with a time out monitor improves utilisation of an AI safety authentication system in ophthalmic surgery: a 1-year before-after study.

Tabuchi Hitoshi H, Ishitobi Naofumi N, Tanabe Mao M, Nakaniida Yuta Y et al.

PubMedInternational journal of pharmaceutics: X2026-10-20

Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.

Li Zhipeng Z, Yan Keda K, Rong Ning N, Sun Shujie S et al.

ROS-related ophthalmic diseases span the ocular surface as well as the anterior and posterior segments of the eye. Dry eye disease (DED), glaucoma, diabetic retinopathy (DR) and age-related macular degeneration (AMD) have distinct anatomical targets but share common pathophysiological features, including oxidative stress, inflammation, vascular dysfunction, epithelial injury or neurodegeneration. Conventional ocular drug delivery and therapeutic modalities are hindered by severe limitations, including low bioavailability in the posterior segment of the eye and the requirement for frequent invasive administration. Nanozymes, an emerging class of therapeutic agents that integrate the properties of nanomaterials with natural enzyme-like catalytic activity, can efficiently scavenge excess reactive oxygen species (ROS) in focal lesions, modulate inflammatory factors, and remodel the pathological microenvironment, thereby providing a novel approach to the treatment of ROS-related ophthalmic diseases. This review systematically elucidates the core characteristics and therapeutic mechanisms of four major categories of nanozymes, namely metal-based, metal oxide-based, carbon-based, and composite nanozymes. To overcome physiological barriers in ocular drug delivery, such as the cornea and the blood-retinal barrier (BRB), we discuss active targeted delivery strategies based on mucin-binding retention, biomimetic cell membrane coating, and molecular ligand-mediated targeting. Furthermore, we summarize the development of intelligent and controlled-release systems in response to specific pathological microenvironments, such as ROS, pH values, and others. Additionally, this review details the latest cutting-edge applications and therapeutic efficacies of nanozymes in specific ophthalmic diseases, including AMD, DR, dry eye disease, and glaucoma. Finally, we highlight the challenges of long-term biosafety evaluation in the bench-to-bedside clinical translation of nanozymes and provide perspectives on future research directions for developing multi-stimuli-responsive synergistic nanodelivery systems.

PubMedBeyoglu eye journal2026-10-20

Cidofovir-Induced Bilateral Uveitis, Hypotony and Choroidal Effusion: A Case Report.

Çimen Yasin Y, Songür Habibullah Saltuk HS, Uçar Mukaddes Kübra MK, Yılmaz Alper Can AC

Cidofovir is an antiviral agent used in the treatment of viral infections but is associated with ocular toxicities. We report a case of a 71-year-old immunocompromised woman who developed bilateral anterior uveitis, marked hypotony, and choroidal effusion following intravenous cidofovir treatment for refractory herpes simplex virus type 2 infection. Ophthalmic examination and multimodal imaging, including optical coherence tomography and ocular ultrasonography, confirmed bilateral choroidal folds and effusion. Extensive systemic evaluation excluded infectious, inflammatory, and autoimmune etiologies. The close temporal relationship between cidofovir administration and symptom onset supported a diagnosis of cidofovir-induced ocular toxicity. Discontinuation of cidofovir and initiation of intensive topical corticosteroid therapy resulted in clinical improvement. This case highlights the importance of early recognition of cidofovir-related ocular adverse effects and the need for close ophthalmic monitoring during therapy.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about carteolol